Gsk (GSK) Short-term Investments (2009 - 2026)

Gsk (GSK) has 9 years of Short-term Investments data on file, last reported at $161.0 million in Q4 2025.

• In Q4 2025, Short-term Investments rose 15.05% year-over-year to $161.0 million; the TTM figure through Dec 2025 stood at $161.0 million (up 15.05% YoY), while the FY2025 annual figure was $161.0 million, up 15.05% from the prior year.
• Short-term Investments climbed to $161.0 million in Q4 2025, from $139.9 million in the prior quarter.
• Across five years, Short-term Investments topped out at $4.8 billion in Q4 2022 and bottomed at $139.9 million in Q4 2024.
• A 4-year average of $2.0 billion and a median of $1.4 billion in 2023 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2024 — Short-term Investments plunged 94.89% — and 2025, when it advanced 15.05%.
• Year by year, Short-term Investments stood at $4.8 billion in 2022, then plunged by 42.94% to $2.7 billion in 2023, then plunged by 94.89% to $139.9 million in 2024, then grew by 15.05% to $161.0 million in 2025.
• The last three Short-term Investments figures came in at $161.0 million (Q4 2025), $139.9 million (Q4 2024), and $2.7 billion (Q4 2023), per Business Quant data.

Peer Comparison